Emergent BioSolutions Snags $1.25B Contract to Provide Anthrax Vaccine to Feds

Rockville, MD-based Emergent Biosolutions (NYSE: EBS)  today announced it has landed a contract worth $1.25 billion over five years to provide the federal government with 44.75 million doses of BioThrax, the only vaccine licensed by the U.S. Food and Drug Administration to protect against anthrax infection. The company will manufacture the vaccine at its facility in Lansing, MI.

In 2006, former Michigan Governor Jennifer Granholm announced state and local tax credits valued at more than $15 million in support of a proposed 50,000-square-foot expansion project at the Lansing facility. Emergent also has a Seattle R&D operation, which it obtained last year through its acquisition of Trubion Pharmaceuticals.

Author: Sarah Schmid Stevenson

Sarah is a former Xconomy editor. Prior to joining Xconomy in 2011, she did communications work for the Michigan Economic Development Corporation and the Michigan House of Representatives. She has also worked as a reporter and copy editor at the Missoula Independent and the Lansing State Journal. She holds a bachelor's degree in Journalism and Native American Studies from the University of Montana and proudly calls Detroit "the most fascinating city I've ever lived in."